康缘药业：关于公司部分董事、高级管理人员自愿增持公司股份计划的公告

Core Viewpoint - Kangyuan Pharmaceutical announced that several key executives plan to increase their shareholding in the company, reflecting their confidence in its future development and long-term investment value [1] Group 1: Executive Shareholding Increase - The executives, including the general manager and several vice presidents, intend to purchase a total of no less than 120,000 shares within one month from the announcement date [1] - The shares to be purchased are from the company's 2022 restricted stock incentive plan [1]